Sarcomas | Specialty

The OncLive Sarcomas/TGCT condition center page is a comprehensive resource for clinical news and expert insights on tenosynovial giant cell tumor (TGCT), soft tissue sarcoma, gastrointestinal stromal tumor, Ewing sarcoma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in sarcomas and TGCT.

Importance of Surgery and Radiation in Advanced STS

October 21st 2015

Integrating Community Oncologists Into the Multidisciplinary Team

October 21st 2015

Key Members of the Multidisciplinary Team

October 21st 2015

Implementation of Multidisciplinary Sarcoma Care

October 21st 2015

Multidisciplinary Assessment of Soft Tissue Sarcomas

October 21st 2015

Accurately Diagnosing Soft Tissue Sarcoma

October 21st 2015

Incidence and Subtypes of Advanced Soft Tissue Sarcoma

October 21st 2015

Treating Bone and Soft Tissue Sarcomas

October 16th 2015

Determining the best course of treatment for sarcomas of the bone and soft tissues is a complex process.

Demetri Interprets Survival Outcomes for Trabectedin in Soft Tissue Sarcomas

October 8th 2015

George D. Demetri, MD, expands on the challenges with overall survival as a primary outcome measure, the potential of trabectedin in soft tissue sarcomas, and the significance of a recent trial.

FDA Grants Priority Review to Eribulin for Soft Tissue Sarcoma

September 30th 2015

The FDA has granted a priority review designation to eribulin mesylate as a treatment for patients with soft tissue sarcoma following an anthracycline and at least one other regimen.

Trabectedin OS Data Unclear in Phase III Sarcoma Study

September 26th 2015

The final analysis of phase III data for trabectedin were consistent with interim results by showing a lack of improvement for the primary endpoint of overall survival in patients with advanced soft tissue sarcoma.

Trabectedin Effective in Heavily Pretreated Metastatic Soft Tissue Sarcomas

September 16th 2015

Trabectedin demonstrated superior disease control compared with dacarbazine in heavily pretreated patients with advanced soft tissue sarcoma.

Regulatory Approval Sought for Eribulin in Soft Tissue Sarcoma

July 30th 2015

An application has been submitted to the FDA for eribulin mesylate (Halaven) as a treatment for patients with soft tissue sarcoma following an anthracycline and at least one other regimen.

Dr. George Demetri on Trabectedin for Sarcomas

July 24th 2015

George D. Demetri, MD, Director, Center for Sarcoma and Bone Oncology Senior Vice President for Experimental Therapeutics, Professor of Medicine, Harvard Medical School, Dana Farber Cancer Center, discusses a phase III study of trabectedin verus dacarbazine for the treatment of patients with advanced liposarcoma (LPS) or leiomyosarcoma (LMS).

Regulatory Review of Trabectedin for Advanced STS

July 2nd 2015

Chemotherapy for Advanced Sarcoma

July 2nd 2015

Treating Refractory or Recurrent Soft Tissue Sarcoma

July 2nd 2015

Factors Impacting the Classification and Diagnosis of STS

July 2nd 2015

Dr. Tap on Olaratumab/Doxorubicin Combination in Soft Tissue Sarcomas

June 5th 2015

William Tap, MD, Medical Oncologist, Chief, Sarcoma Medical Oncology Service Memorial Sloan Kettering Cancer Center discusses the benefits of a olaratumab and doxorubicin combination treatment for advanced soft tissue sarcomas.

Dr. Van Tine on Trabectedin for Leiomyosarcoma and Liposarcoma

June 3rd 2015

Brian A. Van Tine, MD, PhD, Assistant Professor Department of Medicine Siteman Cancer Center, Washington University School of Medicine, discusses trabectedin (Yondelis) for the treatment of soft tissue sarcomas.